Health insurance possible for Herceptin in minor breast cancer patients

In the case of Roche’s Herceptin (trastuzumab), the government is set to expand its support for patients suffering from earlier stage breast cancer who have not shown any metastasis in lymph node but with tumor size of more than 1 cm.

Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor. Antibodies are molecules from the immune system that bind selectively to diffe...